13F Holdings
中文EN

REPL Replimune Group, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1737953 · Fiscal year ends 03/31

Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY12.6%
TTM EPS YoY19.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-115.8%
ROA-71.0%
ROIC (approx.)-209.7%
Asset turnover—

Leverage & solvency

Liabilities / assets45.2%
Debt / equity0.49x
Current ratio7.11x
Interest coverage-30.18x

Cash quality & payout

Operating cash flow / net income0.91x
Accruals ratio-6.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-03-31FY20252025-03-31FY20242024-03-31FY20232023-03-31FY20222022-03-31
Income statement
Revenue—————
R&D expense$221.18M$189.45M$174.96M$126.53M$79.55M
SG&A expense$98.73M$72.18M$59.81M$50.55M$38.77M
Operating income-$319.92M-$261.63M-$234.77M-$177.08M-$118.31M
Interest expense$6.80M$5.78M$4.50M$1.96M$0
Pretax income-$314.49M-$246.83M-$215.39M-$174.00M-$118.04M
Income tax-$551,000$468,000$408,000$288,000$0
Net income-$313.94M-$247.30M-$215.79M-$174.28M-$118.04M
EBITDA-$316.59M-$258.12M-$232.12M-$174.63M-$116.17M
EPS (basic)-3.38-3.07-3.24-2.99-2.26
EPS (diluted)-3.38-3.07-3.24-2.99-2.26
Weighted avg. shares (diluted)92.80M80.56M66.57M58.21M52.21M
Balance sheet
Cash & equivalents$209.02M$112.82M$76.16M$148.23M$107.58M
Short-term investments$59.87M$372.69M$346.21M$436.80M$289.71M
Inventory$0————
Current assets$279.12M$495.88M$433.67M$592.60M$403.98M
PP&E, net$12.97M$13.74M$10.48M$7.48M$7.93M
Total assets$332.39M$551.33M$487.72M$646.59M$461.19M
Current liabilities$58.23M$62.36M$40.44M$33.83M$20.76M
Long-term debt$83.31M$46.38M$44.81M$28.65M$0
Total debt$83.31M$46.38M$44.81M$28.65M$0
Total liabilities$166.23M$135.49M$113.21M$91.30M$49.96M
Shareholders' equity$166.16M$415.84M$374.51M$555.29M$411.23M
Net debt-$125.72M-$66.44M-$31.35M-$119.58M-$107.58M
Shares outstanding82.72M77.09M61.42M56.68M47.34M
Cash flow statement
Operating cash flow-$280.34M-$192.25M-$185.47M-$128.05M-$82.18M
Capital expenditure$4.22M$6.69M$5.66M$2.27M$2.34M
Free cash flow-$284.57M-$198.94M-$191.13M-$130.32M-$84.52M
Investing cash flow$310.84M-$23.80M$97.20M-$142.50M-$1.81M
Financing cash flow$66.29M$252.40M$16.28M$311.30M$6.60M
Depreciation & amortization$3.33M$3.50M$2.65M$2.45M$2.15M
Stock-based compensation$32.27M$35.04M$34.12M$28.13M$24.25M

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.